ArrayExpress Uploader05145Tetracycline-mediated repression of MYCN transgeneTetracycline-mediated repression of MYCN transgeneTetracycline-mediated repression of MYCN transgeneexpression of MYCN transgeneexpression of MYCN transgeneexpression of MYCN transgenearrayexpress_sid4[u'MYCN is an oncogene amplified in approximately 20% of all neuroblastomas and 50% of high risk neuroblastoma. It is a transcription...20145147E-MEXP-2340/profile/8773/arrayexpressuploader16celllineneuroblastomaproteinDec.12, 2014Falsetranscription-profiling-of-human-neuroblastoma-c-6E-MEXP-2340_A-AFFY-44Transcription profiling of human neuroblastoma cell line SHEP expressing a MYNC trasngene against controls which have the transgene silenced by tetracyclineSep.22, 2014[u'MYCN is an oncogene amplified in approximately 20% of all neuroblastomas and 50% of high risk neuroblastoma. It is a transcription factor regulating the expression of genes involved in proliferation and apoptosis.We would like to identify genes potentially regulated by MYCN in a conditional MYCN expression system. The SHEP Tet21N system is a conditional, tetracycline-regulated MYCN expression system established in the MYCN non-amplified SHEP neuroblastoma cell line (Lutz et al., 1996). Expression of MYCN is switched off by the addition of tetracycline to the growth medium. Levels of MYCN protein and RNA in the absence of tetracycline are comparable with those present in MYCN amplified cell lines (Bell et al., 2006).', {u'br': None}, {u'br': None}, {u'br': None}, {u'br': None}, u'By performing microarray analyses on the Tet21n cell lines in the presence and absence of MYCN we hope to identify genes whose expression had been altered by MYCN either upregulated or downregulated and may be potential MYCN targets. The altered expression of some of these genes will then be validated using quantitative RTPCR and a selection will be further investigated to determine if they are MYCN transcriptional targets and may be potential candidates for anti-MYCN therapies for neuroblastoma', {u'br': None}, {u'br': None}, {u'br': None}, {u'br': None}, u'Specific objectives', {u'br': None}, {u'br': None}, u'1) To investigate genes which are altered by 2 fold or more in the presence of or absence of MYCN in Tet21N cells.', {u'br': None}, {u'br': None}, {u'br': None}, {u'br': None}, u'Refs:', {u'br': None}, {u'br': None}, u'Bell, E., Premkumar, R., Carr, J., Lu, X., Lovat, P.E., Kees, U.R., Lunec, J. & Tweddle, D.A. (2006). The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle, 5, 2639-47.', {u'br': None}, {u'br': None}, u'Lutz, W., Stohr, M., Schurmann, J., Wenzel, A., Lohr, A. & Schwab, M. (1996). Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene, 13, 803-12.']http://www.ebi.ac.uk/arrayexpress/experiments/E-MEXP-2340humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-MEXP-2340/samples/